Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 1999

View Archived Issues

SuperGen to acquire Sparta stock and development portfolio

ZymeTx reports progress in development programs

Nippon Kayaku: Annual Report 1998

55 new chemical entities in the combined AstraZeneca pipeline

Phase II trial of G-3139 in NHL patients to commence at Royal Marsden Hospital

Monsanto: Q4 and year-end 1998 highlights

Searle's celecoxib: the first COX-2 inhibitor reaches the market

Pfizer's new macrolide antibiotics presented in patent literature

Beyond Viagra: FDA reviews new product approvals in 1998

Potent heterocyclic antithrombotic agents discovered by Lilly

Neurotransmitter reuptake-inhibitory piperidines designed at NeuroSearch

British Biotech continues search for MMP inhibitors

Preparation and use of neuronal NOS inhibitors disclosed by Astra

New 5-HT4 receptor ligands from Synthelabo, their synthesis and use

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Therapeutic advantages of paricalcitol further defined

Alpha-Beta Technology discontinues phase III trial of Betafectin

Oral L-arginine compared to placebo for efficacy in interstitial cystitis

Glaxo Wellcome and PowderJect expand DNA vaccine collaboration

Searle drops development of gpIIb/IIIa receptor antagonists

New insulin sensitizer is a coligand for PPARalpha and PPARgamma receptors

L-754030 will enter phase III testing for emesis

Another significant market introduction for basiliximab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...